| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H6F2N4O |
| Molecular Weight | 284.2204 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CN=C(C=C1)C2=NOC(=N2)C3=CC(F)=CC(=C3)C#N
InChI
InChIKey=RBSPCALDSNXWEP-UHFFFAOYSA-N
InChI=1S/C14H6F2N4O/c15-10-1-2-12(18-7-10)13-19-14(21-20-13)9-3-8(6-17)4-11(16)5-9/h1-5,7H
| Molecular Formula | C14H6F2N4O |
| Molecular Weight | 284.2204 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
AZD-9272 is an orally bioavailable and brain-penetrant potent and selective mGluR5 negative allosteric modulator. It exhibits high selectivity for mGluR5 over other mGlu receptors. It had been in phase I clinical trials for the treatment of gastroesophageal reflux disease and neuropathic pain. Single doses of the centrally acting mGluR5-antagonist AZD-9272 did not reduce C-fibre evoked pain, central sensitization or flare reaction in the study aimed to investigate its effect on electrically induced pain, central sensitization and axon reflex flare.
CNS Activity
Originator
Approval Year
Doses
Sourcing
Sample Use Guides
3-24 mg single dose (the maximum tolerated dose is 24 mg)
Route of Administration:
Oral
[3H]AZD9272 binding in rat striatum was of high affinity and finite capacity (Kd = 9.4 ± 1.9 nM; Bmax = 1553 ± 474 fmol/mg T.E.; ±SD, n = 5) and could be inhibited by MPEP, MTEP and AZD6538 (IC50 AZD6538, 14.5 ± 4.7 nM; MTEP, 24 ± 6.1; n = 2, confirming that these compounds bind to a common site also at the native mGluR5 in rat brain sections.
